Chellse Gazda, M.D.
Endocrinology, Diabetes & Metabolism Physician in Dallas, Texas.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 7,852 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Chellse Gazda, M.D. reported a CMS MIPS final score of 74.6/100 - below the 83.1 national average - and filed 207 Medicare Part D claims in 2023.
- 74.6/100
- MIPS score · -9 vs avg
- 207
- Part D claims, 2023
- 0%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Chellse Gazda, M.D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
75 12th percentile higher than 12% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Chellse Gazda, M.D. sits
This provider among endocrinology, diabetes & metabolism physician peers
Across the 2,521 endocrinology, diabetes & metabolism physician providers who report both Medicare Part D prescribing and a MIPS quality score, Chellse Gazda, M.D. writes more Part D claims than 7% of them and scores higher on MIPS quality than 14% - placing this provider in the lower-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one endocrinology, diabetes & metabolism physician peer from a representative sample of 60; the gold marker is Chellse Gazda, M.D.. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
Chellse Gazda, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Chellse Gazda, M.D.?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Texas
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Texas providers
Endocrinology, Diabetes & Metabolism Physician ranks #95 among Texas's specialties (0.1% of in-state providers)
Each bar is a specialty's share of the Texas provider total, by primary NUCC taxonomy. The highlighted bar is Endocrinology, Diabetes & Metabolism Physician; the long tail of smaller specialties is omitted for legibility.
Medicare quality performance, MIPS
Chellse Gazda, M.D.'s 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average
- MIPS Final Score
- 74.6/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Endocrinology, Diabetes & Metabolism Physician) - 74.6/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Endocrinology, Diabetes & Metabolism Physician US NPIs
74.6/100 MIPS final score - 8.5 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Endocrinology, Diabetes & Metabolism Physician. Quality dim: 56.1. Cost dim: 59.2.
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Chellse Gazda, M.D. appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding M.D. credentials at 2001 INWOOD RD, Dallas, TX, 75390, with a listed phone of (214) 645-2800. NPI 1659765170 was issued on 03/23/2015.
Medicare Part D records for calendar year 2023 show 207 prescription claims written by this provider, covering 69 Medicare beneficiaries and totaling roughly $197K in drug spend, split 66% brand-name and 0% generic by claim count. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 74.6/100 for the 2023 performance year (Quality 56.1, Cost 59.2), compared with the national average of 83.1.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1659765170 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | M.D. |
| Gender | Female |
| NPI Issued | 03/23/2015 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm Chellse Gazda, M.D.'s current license status, disciplinary history, and board certifications with the Texas Medical Board in Texas before relying on this page for a clinical or care decision.
How we sourced this profile
Profile fields combine the CMS NPPES monthly snapshot (provider directory, taxonomy, and address) with calendar-year 2023 Medicare Part D and MIPS public-use files when records are present. NPI 1659765170 is the unique 10-digit identifier CMS uses to link Gazda across every Medicare, Medicaid, and HIPAA-covered transaction. Read full methodology →
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where Chellse Gazda, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Chellse Gazda, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$597
Largest payer
Boehringer Ingelheim Pharmaceuticals, Inc.
Most common payment type
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - Texas TMB 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 - they are NOT specific to Chellse Gazda, M.D.. To verify Chellse Gazda, M.D.'s current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
66% brand-name claims vs 0% generic, on 207 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 357
- Total Day Supply
- 10,504
- Brand vs Generic
- 66% brand / 0% generic
- Brand Drug Cost
- $196K
Patient Demographics
- Average Patient Age
- 62.4 years
- Avg HCC Risk Score
- 1.96
- Gender Split
- 78% female / 22% male
- Age Distribution
- <65: 30, 65-74: 29, 75-84: N/A, 85+: N/A
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Chellse Gazda, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Ozempic
Ozempic
56 claims
- Mounjaro
Mounjaro
41 claims
- Bupropion Xl 14
Bupropion Xl
14 claims
- Levothyroxine Sodium 11
Levothyroxine Sodium
11 claims
- Metformin Hcl 11
Metformin Hcl
11 claims
| Drug | Claims |
|---|---|
| Ozempic Semaglutide | 56 |
| Mounjaro Tirzepatide | 41 |
| Bupropion Xl Bupropion Hcl | 14 |
| Levothyroxine Sodium | 11 |
| Metformin Hcl | 11 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Endocrinology, Diabetes & Metabolism Physician Overview
How Chellse Gazda, M.D. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
Chellse Gazda, M.D.'s 207 claims are below the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Texas
Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as Gazda.
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the Texas medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Endocrinology, Diabetes & Metabolism Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Texas
Frequently Asked Questions
What is Chellse Gazda, M.D.'s specialty? ▼
How much does Chellse Gazda, M.D. prescribe under Medicare Part D? ▼
What is Chellse Gazda, M.D.'s Medicare quality score? ▼
Where is Chellse Gazda, M.D. located? ▼
What is Chellse Gazda, M.D.'s NPI number? ▼
Does Chellse Gazda, M.D. prescribe more brand-name or generic drugs? ▼
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
What drugs does Chellse Gazda, M.D. prescribe most often? ▼
Does Chellse Gazda, M.D. accept Medicare? ▼
How can I verify Chellse Gazda, M.D.'s credentials? ▼
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology